查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585564

分叉病變市場：按類型、按應用分類 - 2025-2030 年全球預測

Bifurcation Lesions Market by Type (One-Stent, Two-Stent), Application (Coronary Vascular, Peripheral Vascular) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年分叉病變市值為32.3億美元，預計到2024年將達到35.6億美元，複合年成長率為10.63%，到2030年將達到65.6億美元。

分叉病變是冠狀動脈疾病的一種，當動脈粥狀硬化斑塊在血管分叉處或附近形成時就會發生。解決這些病變至關重要，因為它們很複雜，並且可能在經皮冠狀動脈介入治療 (PCI) 期間引起併發症。這些病變需要高度專業化的支架和介入措施，使其成為心血管治療的重要組成部分。人口老化、心血管疾病盛行率增加以及支架留置技術的進步推動了分叉病變干預市場。關鍵的成長要素包括新一代藥物釋放型支架、分叉專用支架以及診斷影像技術的改進以最佳化治療結果。最新的潛在機會在於生物可吸收支架的開發和診斷成像模式的改進，例如光同調斷層掃瞄（OCT），以幫助準確的病變評估和設備定位。鼓勵公司投資研發，以創新解決方案來解決這些具體方面。然而，市場面臨嚴格的監管要求、高昂的手術成本以及需要熟練的心臟科醫師進行複雜干預等挑戰。限制包括支架內血栓症和血管再阻塞的可能性。技術創新的一個有前景的領域是開發專用的分叉設備和成像技術，這些設備和成像技術可以無縫整合到現有的導管實驗室中，從而提高手術的成功率。科技公司和醫療保健提供者之間的合作可以帶來設備創新和手術通訊協定的突破。市場參與企業需要保持敏捷並定期更新其產品，以跟上不斷變化的監管標準和技術進步的步伐。提高介入性心臟病專家技能的培訓計劃也提供了市場擴張機會。儘管存在競爭，但對於那些能夠駕馭監管環境並解決未滿足的臨床需求的公司來說，這個市場具有巨大的潛力。了解分叉病變的微妙性質並繼續與醫療保健提供者進行對話可能是確定策略成長路徑的關鍵。

主要市場統計
基準年[2023] 32.3億美元
預測年份 [2024] 35.6億美元
預測年份 [2030] 65.6億美元
複合年成長率（%） 10.63%

市場動態：快速發展的分叉病變市場的關鍵市場洞察

供給和需求的動態交互作用正在改變分叉病變市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球冠狀動脈疾病盛行率不斷上升
    • 老年人口增加和與老齡化相關的疾病增加
    • 改善醫療基礎設施以及對微創手術的偏好
  • 市場限制因素
    • 該行業缺乏熟練的專業人才
  • 市場機會
    • 持續研發引進新的處理技術
    • 涉及球囊和支架的臨床試驗迅速增加
  • 市場挑戰
    • 嚴格的法規和標準

波特五力：駕馭分岔病變市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解分叉病變市場的外部影響

外部宏觀環境因素對於塑造分叉病變市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解分叉病變市場的競爭狀況

對分叉病變市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV定位矩陣分叉病變市場廠商績效評估

FPNV定位矩陣是評估分叉病變市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了分叉病變市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對分叉病變市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球冠狀動脈疾病盛行率增加
      • 老年人口增加和與老齡化相關的疾病
      • 改善醫療基礎設施並優先考慮微創手術
    • 抑制因素
      • 該行業缺乏熟練的專業人才
    • 機會
      • 持續研發引進新的處理技術
      • 球囊和支架臨床試驗迅速增加
    • 任務
      • 嚴格的法規和標準
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章分叉病變市場：依類型

  • 一個支架
  • 2 個支架

第7章分叉病變市場：依應用分類

  • 冠狀血管
  • 周圍血管

第8章：美洲分叉病變市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太分叉病變市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章：歐洲/中東/非洲分叉病變市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Absolute-DSi
  • B. Braun SE
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health Inc.
  • Cook Group Incorporated
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Olympus Corporation
  • Stryker Corporation
  • Tecomet, Inc.
  • Terumo Corporation
  • Tryton Medical, Inc.
Product Code: MRR-BD6F81433E75

The Bifurcation Lesions Market was valued at USD 3.23 billion in 2023, expected to reach USD 3.56 billion in 2024, and is projected to grow at a CAGR of 10.63%, to USD 6.56 billion by 2030.

Bifurcation lesions, a type of coronary artery disease, occur when atherosclerotic plaques develop at or near a vessel branch. The need to address these lesions is critical due to their complexity and potential risk of procedural complications during percutaneous coronary interventions (PCI). These lesions require highly specialized stents or interventions, making them a pivotal component of cardiovascular treatment. The market for bifurcation lesion interventions is driven by an aging population, increasing prevalence of cardiovascular diseases, and advancements in stenting technologies. Key growth factors include the advent of new-generation drug-eluting stents, bifurcation-specific stents, and enhanced imaging techniques which optimize treatment outcomes. The latest potential opportunities lie in the development of bioresorbable scaffolds and improved imaging modalities such as optical coherence tomography (OCT) which aid in precise lesion assessment and device positioning. Companies are encouraged to invest in R&D to innovate solutions that address these specific aspects. However, the market faces challenges like stringent regulatory requirements, high procedural costs, and the need for skilled cardiologists to perform complex interventions. Limitations include potential stent thrombosis or restenosis. A promising area of innovation is the development of dedicated bifurcation devices and imaging technology that can seamlessly integrate into existing catheter labs, thus enhancing procedural success rates. Collaboration between technology firms and medical institutions could lead to breakthroughs in device innovation and procedural protocols. Market participants need to be agile, regularly updating their offerings to meet evolving regulatory standards and technological advancements. Training programs to improve the skills of interventional cardiologists also present market expansion opportunities. While competitive, the market holds significant promise for businesses that can navigate the regulatory landscape and address unmet clinical needs. Understanding the nuanced nature of bifurcation lesions and continuing dialogue with healthcare providers will be key in identifying strategic growth avenues.

KEY MARKET STATISTICS
Base Year [2023] USD 3.23 billion
Estimated Year [2024] USD 3.56 billion
Forecast Year [2030] USD 6.56 billion
CAGR (%) 10.63%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bifurcation Lesions Market

The Bifurcation Lesions Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of coronary artery diseases globally
    • Rising elderly population and the medical ailments associated with age
    • Improving healthcare infrastructure coupled with preference for minimally invasive surgeries
  • Market Restraints
    • Lack of skilled professional in the industry
  • Market Opportunities
    • Ongoing research and development toward introduction novel treatment techniques
    • Surge in the number of clinical trials on balloons and stents
  • Market Challenges
    • Stringent regulations and standards

Porter's Five Forces: A Strategic Tool for Navigating the Bifurcation Lesions Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bifurcation Lesions Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bifurcation Lesions Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bifurcation Lesions Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bifurcation Lesions Market

A detailed market share analysis in the Bifurcation Lesions Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bifurcation Lesions Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bifurcation Lesions Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bifurcation Lesions Market

A strategic analysis of the Bifurcation Lesions Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bifurcation Lesions Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Absolute-DSi, B. Braun SE, Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cardinal Health Inc., Cook Group Incorporated, Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Medtronic PLC, MicroPort Scientific Corporation, Olympus Corporation, Stryker Corporation, Tecomet, Inc., Terumo Corporation, and Tryton Medical, Inc..

Market Segmentation & Coverage

This research report categorizes the Bifurcation Lesions Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across One-Stent and Two-Stent.
  • Based on Application, market is studied across Coronary Vascular and Peripheral Vascular.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of coronary artery diseases globally
      • 5.1.1.2. Rising elderly population and the medical ailments associated with age
      • 5.1.1.3. Improving healthcare infrastructure coupled with preference for minimally invasive surgeries
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled professional in the industry
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development toward introduction novel treatment techniques
      • 5.1.3.2. Surge in the number of clinical trials on balloons and stents
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and standards
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bifurcation Lesions Market, by Type

  • 6.1. Introduction
  • 6.2. One-Stent
  • 6.3. Two-Stent

7. Bifurcation Lesions Market, by Application

  • 7.1. Introduction
  • 7.2. Coronary Vascular
  • 7.3. Peripheral Vascular

8. Americas Bifurcation Lesions Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Bifurcation Lesions Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Bifurcation Lesions Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Absolute-DSi
  • 3. B. Braun SE
  • 4. Becton, Dickinson and Company
  • 5. BIOTRONIK SE & Co. KG
  • 6. Boston Scientific Corporation
  • 7. Cardinal Health Inc.
  • 8. Cook Group Incorporated
  • 9. Johnson & Johnson Services, Inc.
  • 10. Koninklijke Philips N.V.
  • 11. Medtronic PLC
  • 12. MicroPort Scientific Corporation
  • 13. Olympus Corporation
  • 14. Stryker Corporation
  • 15. Tecomet, Inc.
  • 16. Terumo Corporation
  • 17. Tryton Medical, Inc.

LIST OF FIGURES

  • FIGURE 1. BIFURCATION LESIONS MARKET RESEARCH PROCESS
  • FIGURE 2. BIFURCATION LESIONS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIFURCATION LESIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BIFURCATION LESIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BIFURCATION LESIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BIFURCATION LESIONS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BIFURCATION LESIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIFURCATION LESIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIFURCATION LESIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIFURCATION LESIONS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY ONE-STENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY TWO-STENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY CORONARY VASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIFURCATION LESIONS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES BIFURCATION LESIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA BIFURCATION LESIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM BIFURCATION LESIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM BIFURCATION LESIONS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. BIFURCATION LESIONS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. BIFURCATION LESIONS MARKET, FPNV POSITIONING MATRIX, 2023